Screener
Ligand Pharmaceuticals LGND AT220 — Financial Royalty Assets, Allowance
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
| Others | 5,729 | (212) | 5,517 | 5,769 | (214) | 5,555 |
| Total financial royalty assets, net | $209,699 | $(2,489) | $207,210 | $222,375 | $(2,706) | $219,669 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's AT220 — financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported AT220 — financial royalty assets, allowance of $109K in Q2 2026.
- What does AT220 — financial royalty assets, allowance mean?
- This metric reflects the cumulative valuation adjustments, such as expected credit losses or impairment reserves, applied to the royalty assets of the AT220 segment. It acts as a contra-asset account that accounts for potential risks or declines in the projected future cash flows from these specific royalty streams. A significant increase in this allowance may signal management's concern regarding the commercial viability or collectability of the underlying pharmaceutical partnerships.
Ask your AI about Ligand Pharmaceuticals's at220 — financial royalty assets, allowance.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude